Schabel Fm

2.7k total citations · 1 hit paper
60 papers, 2.1k citations indexed

About

Schabel Fm is a scholar working on Molecular Biology, Oncology and Organic Chemistry. According to data from OpenAlex, Schabel Fm has authored 60 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Molecular Biology, 14 papers in Oncology and 10 papers in Organic Chemistry. Recurrent topics in Schabel Fm's work include Cancer therapeutics and mechanisms (8 papers), Acute Lymphoblastic Leukemia research (8 papers) and Synthesis and biological activity (5 papers). Schabel Fm is often cited by papers focused on Cancer therapeutics and mechanisms (8 papers), Acute Lymphoblastic Leukemia research (8 papers) and Synthesis and biological activity (5 papers). Schabel Fm collaborates with scholars based in United States. Schabel Fm's co-authors include Skipper He, Laster Wr, Griswold Dp, Trader Mw, Corbett Th, Wilcox Ws, Montgomery Ja, Brockman Rw, Mellett Lb and Linda Simpson‐Herren and has published in prestigious journals such as PubMed and Munich Personal RePEc Archive (Ludwig Maximilian University of Munich).

In The Last Decade

Schabel Fm

59 papers receiving 1.7k citations

Hit Papers

cis-Dichlorodiammineplatinum(II): combination chemotherap... 1980 2026 1995 2010 1980 100 200 300

Peers

Schabel Fm
Comparison fields: 5 of 106
  • Oncology 941
  • Molecular Biology 766
  • Pulmonary and Respiratory Medicine 335
  • Cancer Research 251
  • Hematology 220
Replace Daniel Glaubiger with:
Daniel Glaubiger United States
Laster Wr United States
P. Hilgard Germany
Eric Scholar United States
David A. Van Echo United States
Holland Jf United States
Tina Colombo Italy
P R Twentyman United Kingdom
Gerald J. Goldenberg Canada
Barbara A. Moroson United States
Daniel Glaubiger United States View profile →
Citations per field, relative to Schabel Fm
Schabel Fm · 1×
Citations per year, relative to Schabel Fm
Schabel Fm · 1×

Countries citing papers authored by Schabel Fm

Since Specialization
Citations

This map shows the geographic impact of Schabel Fm's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Schabel Fm with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Schabel Fm more than expected).

Fields of papers citing papers by Schabel Fm

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Schabel Fm. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Schabel Fm. The network helps show where Schabel Fm may publish in the future.

Co-authorship network of co-authors of Schabel Fm

This figure shows the co-authorship network connecting the top 25 collaborators of Schabel Fm. A scholar is included among the top collaborators of Schabel Fm based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Schabel Fm. Schabel Fm is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
# Work Indexed citations
1
Tumor stem cell heterogeneity: implications with respect to classification of cancers by chemotherapeutic effect.
49
2
cis-Dichlorodiammineplatinum(II): combination chemotherapy and cross-resistance studies with tumors of mice. breakdown →
357
3
Fundamentals in cancer chemotherapy: introduction.
1
4
Therapeutic potentiation of nitrosoureas using chlorpromazine and caffeine in the treatment of murine tumors.
7
5
Biology and therapeutic response of a mouse mammary adenocarcinoma (16/C) and its potential as a model for surgical adjuvant chemotherapy.
82
6
Experimental therapeutics and kinetics: selection and overgrowth of specifically and permanently drug-resistant tumor cells.
54
7
Studies with 2,5-piperazinedione, 3,6-bis(5-chloro-2-piperidyl)-,dihydrochloride. III. Biochemical and therapeutic effects in L1210 leukemias sensitive and resistant to alkylating agents: comparison with melphalan, cyclophosphamide, and BCNU.
3
8
Basic and therapeutic trial results obtained in the spontaneous AK leukemia (lymphoma) model-end of 1971.
23
9
The "sensitivity" of resting and dividing cells.
3
10
Implications of biochemical, cytokinetic, pharmacologic, and toxicologic relationships in the design of optimal therapeutic schedules.
215
11
Response to therapy of spontaneous, first passage, and long passage lines of AK leukemia.
23
12
Chemotherapy of leukemia L1210 by 6-mercaptopurine (NSC-755) in combination with 6-methylthiopurine ribonucleoside (NSC-40774).
4
13
Experimental evaluation of potential anticancer agents. XXI. Scheduling of arabinosylcytosine to take advantage of its S-phase specificity against leukemia cells.
178
14
VIRUS CHEMOTHERAPY - WHY AND HOW.
2
15
Experimental evaluation of potenital anticancer agents. XVII. Kinetics of growth and regression after treatment of certain solid tumors.
35
16
EXPERIMENTAL EVALUATION OF POTENTIAL ANTICANCER AGENTS. XIV. FURTHER STUDY OF CERTAIN BASIC CONCEPTS UNDERLYING CHEMOTHERAPY OF LEUKEMIA.
53
17
Development of Friend leukemia virus in spleen and plasma of Swiss mice.
2
18
Experimental evaluation of potential anticancer agents. X. A specificity test for distinguishing false positives.
2
19
Experimental evaluation of potential anticancer agents. II. Studies on the growth characteristics, metastases, and drug response of hamster neoplasms of diverse "sites of origin".
7
20
Studies on the mechanism of action and anticancer activity of N-methylformamide.
17

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026